Vera Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 89.06 million compared to USD 32.61 million a year ago. Basic loss per share from continuing operations was USD 3.35 compared to USD 2.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.69 USD | +4.45% | -5.01% | +177.57% |
May. 10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
May. 09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+177.57% | 2.34B | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.39% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022